Pioglitazone, a PPAR-γ agonist, downregulates the inflammatory response from cutaneous leishmaniasis patients without interfering in the killing of L. braziliensis by monocytes

Figure 1 - STRING protein-protein network.<br>Figure 2 - Ability of pioglitazone to decrease the immune response via TLR2 and TLR4 activation.<br><br>Figure 3 - Pioglitazone down-regulates the production of inflammatory cytokines.<br><br>Figure 4 - Blocking PPAR-γ prevents cytokine production by pioglitazone. <br><br>Figure 5 - Pioglitazone increases the killing of <i>L. braziliensis</i> by monocytes. <br><br>Figure 6 – Pioglitazone does not interfere in <i>L. braziliensis</i>-induced ROS production. <br><br>Figure 7 – Effects of pioglitazone on cell viability. <br><br>Figure 8 - Pioglitazone decreases the production of inflammatory cytokines in CL lesion.<br>